Your browser doesn't support javascript.
loading
A patient with refractory high-grade B-cell lymphoma and rapid progression under CAR-T-cell therapy was successfully salvaged with inotuzumab- ozogamicin.
Strüßmann, T; Wäsch, R; Scherer, F; Mutter, J A; Pfeifer, D; Bartsch, I; Giesler, S; Graziani, G; Duyster, J; Finke, J; Marks, R.
Afiliación
  • Strüßmann T; Department of Medicine I, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
  • Wäsch R; Department of Medicine I, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
  • Scherer F; Department of Medicine I, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
  • Mutter JA; German Cancer Consortium (DKTK) partner site Freiburg and German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Pfeifer D; Department of Medicine I, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
  • Bartsch I; Faculty of Biology, University of Freiburg, Freiburg, Germany.
  • Giesler S; Department of Medicine I, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
  • Graziani G; Department of Medicine I, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
  • Duyster J; Department of Medicine I, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
  • Finke J; Department of Medicine I, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
  • Marks R; Department of Medicine I, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Leuk Lymphoma ; 63(9): 2260-2262, 2022 09.
Article en En | MEDLINE | ID: mdl-35593017

Texto completo: 1 Colección: 01-internacional Asunto principal: Linfoma de Células B Grandes Difuso / Receptores Quiméricos de Antígenos Límite: Humans Idioma: En Revista: Leuk Lymphoma Asunto de la revista: HEMATOLOGIA / NEOPLASIAS Año: 2022 Tipo del documento: Article País de afiliación: Alemania

Texto completo: 1 Colección: 01-internacional Asunto principal: Linfoma de Células B Grandes Difuso / Receptores Quiméricos de Antígenos Límite: Humans Idioma: En Revista: Leuk Lymphoma Asunto de la revista: HEMATOLOGIA / NEOPLASIAS Año: 2022 Tipo del documento: Article País de afiliación: Alemania